Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Thaena is a private Portland, Oregon microbiome-focused health company developing and selling human-derived complex postbiotic products. Its flagship product, ThaenaBiotic, is marketed as the world’s first stool-derived complex postbiotic supplement and is produced from rigorously screened healthy human donor material that is sterilized, refined, and shelf-stabilized. The company positions its approach as restoring missing postbiotic signals to support gut ecosystem recovery, resilience, and broader health outcomes including longevity-related biology. In addition to commercialization of ThaenaBiotic, Thaena appears to be building an IP-backed platform around fecal-derived sterilized postbiotic compositions and related applications in anti-aging and neurotherapeutic settings. The business sits at the intersection of microbiome science, consumer health, and emerging biotech-enabled wellness.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Thaena.